Abstract

It was established that the administration of an aqueous solution of bis(µ-tartrato)di(μ-hydroxy) germanate (IV) triethanolammonium to animals daily for 2 months at a dose of the active substance of 10 mg/kg of the animal’s weight leads to inhibition of the total activity of the alkaline phospholipase A₂ of mononuclear cells. The results of the study can be used to correct lipid metabolism in the development of disorders in hyperlipidemia. This makes it possible to expand the scope of use of the studied substance and create new pharmaceuticals based on bis(µ-tartrato)di(μ-hydroxy) germanate (IV) triethanolammonium prevent and inhibit the development of hyperlipidemia.

中文翻译：

---

双（µ-Tratrato）二（µ-羟基）锗酸酯（IV）三乙醇铵作为单核碱性磷酸酶A 2抑制剂

摘要

已确定每天以动物体重10 mg / kg的活性物质剂量向动物施用双（μ-酒石酸）二（μ-羟基）锗酸（IV）三乙醇铵水溶液，持续2个月导致单核细胞碱性磷脂酶A ₂的总活性受到抑制。该研究结果可用于纠正高脂血症疾病发展过程中的脂质代谢。这使得有可能扩大研究物质的使用范围，并开发出基于双（μ-酒石）二（μ-羟基）锗酸（IV）三乙醇铵的新药物，从而预防和抑制高脂血症的发展。